167 related articles for article (PubMed ID: 19783879)
1. Molecular targeting for treatment of advanced hepatocellular carcinoma.
Song IH
Korean J Hepatol; 2009 Sep; 15(3):299-308. PubMed ID: 19783879
[TBL] [Abstract][Full Text] [Related]
2. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
4. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of hepatocellular carcinoma and molecular therapies.
Mínguez B; Tovar V; Chiang D; Villanueva A; Llovet JM
Curr Opin Gastroenterol; 2009 May; 25(3):186-94. PubMed ID: 19387255
[TBL] [Abstract][Full Text] [Related]
6. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
8. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
9. Signaling pathways in hepatocellular carcinoma.
Sia D; Villanueva A
Oncology; 2011; 81 Suppl 1():18-23. PubMed ID: 22212931
[TBL] [Abstract][Full Text] [Related]
10. Novel molecular therapies in hepatocellular carcinoma.
Faivre S; Bouattour M; Raymond E
Liver Int; 2011 Jan; 31 Suppl 1():151-60. PubMed ID: 21205154
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
Kuzuya T; Tsuchiya K; Izumi N
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1883-86. PubMed ID: 21069944
[No Abstract] [Full Text] [Related]
14. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.
Lord R; Suddle A; Ross PJ
Int J Clin Pract; 2011 Feb; 65(2):182-8. PubMed ID: 21235699
[TBL] [Abstract][Full Text] [Related]
15. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
Lee JM; Han KH
Oncology; 2010 Jul; 78 Suppl 1():167-71. PubMed ID: 20616600
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.
Witjes CD; Verhoef C; Verheul HM; Eskens FA
Neth J Med; 2009 Mar; 67(3):86-90. PubMed ID: 19307678
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
Zender L; Kubicka S
Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
19. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
20. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
Rimassa L; Santoro A
Dig Liver Dis; 2010 Jul; 42 Suppl 3():S273-80. PubMed ID: 20547314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]